<?xml version="1.0" ?>
<document id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d">
  <chunk id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c0" text="Suppression of feline coronavirus replication in vitro by cyclosporin A">
    <entity charOffset="58-71" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c0.e0" ontology_id="CHEBI_4031" text="cyclosporin A" type="chemical"/>
  </chunk>
  <chunk id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1" text="The feline infectious peritonitis virus (FIPV) is a member of the feline coronavirus family that causes FIP, which is incurable and fatal in cats. Cyclosporin A (CsA), an immunosuppressive agent that targets the nuclear factor pathway of activated T-cells (NF-AT) to bind cellular cyclophilins (CyP), dose-dependently inhibited FIPV replication in vitro. FK506 (an immunosuppressor of the pathway that binds cellular FK506-binding protein (FKBP) but not CyP) did not affect FIPV replication. Neither cell growth nor viability changed in the presence of either CsA or FK506, and these factors did not affect the NF-AT pathway in fcwf-4 cells. Therefore, CsA does not seem to exert inhibitory effects via the NF-AT pathway. In conclusion, CsA inhibited FIPV replication in vitro and further studies are needed to verify the practical value of CsA as an anti-FIPV treatment in vivo.">
    <entity charOffset="22-33" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e0" ontology_id="DOID_8283" text="peritonitis" type="disease"/>
    <entity charOffset="147-160" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e1" ontology_id="CHEBI_4031" text="Cyclosporin A" type="chemical"/>
    <entity charOffset="171-194" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e2" ontology_id="CHEBI_35705" text="immunosuppressive agent" type="chemical"/>
    <entity charOffset="227-234" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e3" ontology_id="CHEBI_34922" text="pathway" type="chemical"/>
    <entity charOffset="389-396" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e4" ontology_id="CHEBI_34922" text="pathway" type="chemical"/>
    <entity charOffset="431-438" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e5" ontology_id="CHEBI_16541" text="protein" type="chemical"/>
    <entity charOffset="454-457" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e6" ontology_id="CHEBI_38559" text="CyP" type="chemical"/>
    <entity charOffset="560-563" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e7" ontology_id="CHEBI_55379" text="CsA" type="chemical"/>
    <entity charOffset="617-624" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e8" ontology_id="CHEBI_34922" text="pathway" type="chemical"/>
    <entity charOffset="653-656" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e9" ontology_id="CHEBI_55379" text="CsA" type="chemical"/>
    <entity charOffset="713-720" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e10" ontology_id="CHEBI_34922" text="pathway" type="chemical"/>
    <entity charOffset="737-740" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e11" ontology_id="CHEBI_55379" text="CsA" type="chemical"/>
    <entity charOffset="841-844" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e12" ontology_id="CHEBI_55379" text="CsA" type="chemical"/>
    <pair e1="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e0" e2="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e1" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.p0" relation="true"/>
    <pair e1="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e0" e2="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e2" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.p1" relation="true"/>
    <pair e1="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e0" e2="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e3" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.p2" relation="true"/>
    <pair e1="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e0" e2="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e4" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.p3" relation="true"/>
    <pair e1="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e0" e2="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e5" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.p4" relation="true"/>
    <pair e1="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e0" e2="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e6" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.p5" relation="true"/>
    <pair e1="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e0" e2="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e7" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.p6" relation="true"/>
    <pair e1="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e0" e2="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e8" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.p7" relation="true"/>
    <pair e1="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e0" e2="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e9" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.p8" relation="true"/>
    <pair e1="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e0" e2="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e10" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.p9" relation="true"/>
    <pair e1="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e0" e2="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e11" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.p10" relation="true"/>
    <pair e1="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e0" e2="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.e12" id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c1.p11" relation="true"/>
  </chunk>
  <chunk id="16283e25f01d47898ad2b82d56bd81d5ccf44a5d.c2" text="Authors' contributions YT carried out all experiments, participated in the data collection and analysis, and prepared the manuscript. SO, MI, and ST carried out cell culture and virus preparation. YS performed some of the biochemical experiments and TS carried out luciferase assays. All authors read and approved the final manuscript."/>
</document>
